Institutional investors purchased a net $93.0 thousand shares of TROV during the quarter ended March 2017. This may signal that the smart money is gaining interest in this company as the 18.71% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
KCG AMERICAS LLC Bought 178.4 Thousand shares of Trovagene Inc
TWO SIGMA SECURITIES LLC Bought 87.3 Thousand shares of Trovagene Inc
ELKHORN PARTNERS LP Bought 63.5 Thousand shares of Trovagene Inc